WO2004074499A3 - Combinatorial dna library for producing modified n-glycans in lower eukaryotes - Google Patents

Combinatorial dna library for producing modified n-glycans in lower eukaryotes Download PDF

Info

Publication number
WO2004074499A3
WO2004074499A3 PCT/US2004/005244 US2004005244W WO2004074499A3 WO 2004074499 A3 WO2004074499 A3 WO 2004074499A3 US 2004005244 W US2004005244 W US 2004005244W WO 2004074499 A3 WO2004074499 A3 WO 2004074499A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified
glycosylation
host cells
glycans
mannosidases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/005244
Other languages
French (fr)
Other versions
WO2004074499A2 (en
Inventor
Tillman U Gerngross
Stefan Wildt
Byung-Kwon Choi
Juergen Hermann Nett
Piotr Bobrowicz
Stephen R Hamilton
Robert C Davidson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT04713437T priority Critical patent/ATE469236T1/en
Priority to DE602004027351T priority patent/DE602004027351D1/en
Priority to CA002516440A priority patent/CA2516440A1/en
Priority to JP2006503788A priority patent/JP4875486B2/en
Priority to AU2004213869A priority patent/AU2004213869B2/en
Priority to EP04713437A priority patent/EP1599596B1/en
Application filed by Individual filed Critical Individual
Publication of WO2004074499A2 publication Critical patent/WO2004074499A2/en
Publication of WO2004074499A3 publication Critical patent/WO2004074499A3/en
Priority to IL170347A priority patent/IL170347A/en
Anticipated expiration legal-status Critical
Priority to IL198906A priority patent/IL198906A0/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man5GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.
PCT/US2004/005244 2003-02-20 2004-02-20 Combinatorial dna library for producing modified n-glycans in lower eukaryotes Ceased WO2004074499A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE602004027351T DE602004027351D1 (en) 2003-02-20 2004-02-20 COMBINATIVE DNA LIBRARY FOR THE PREPARATION OF MODIFIED N-GLUCANES IN LOWER EUKARYOTES
CA002516440A CA2516440A1 (en) 2003-02-20 2004-02-20 Combinatorial dna library for producing modified n-glycans in lower eukaryotes
JP2006503788A JP4875486B2 (en) 2003-02-20 2004-02-20 Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
AU2004213869A AU2004213869B2 (en) 2003-02-20 2004-02-20 Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
EP04713437A EP1599596B1 (en) 2003-02-20 2004-02-20 Combinatorial dna library for producing modified n -glycans in lower eukaryotes
AT04713437T ATE469236T1 (en) 2003-02-20 2004-02-20 COMBINATORY DNA LIBRARY FOR PRODUCING MODIFIED N-GLUCANS IN LOWER EUKARYOTES
IL170347A IL170347A (en) 2003-02-20 2005-08-18 Methods for producing modified n-glycans in eukaryotes
IL198906A IL198906A0 (en) 2003-02-20 2009-05-24 Dna encoding a cellular targeting signal peptide and a glycosylation enzyme and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/371,877 2003-02-20
US10/371,877 US7449308B2 (en) 2000-06-28 2003-02-20 Combinatorial DNA library for producing modified N-glycans in lower eukaryotes

Publications (2)

Publication Number Publication Date
WO2004074499A2 WO2004074499A2 (en) 2004-09-02
WO2004074499A3 true WO2004074499A3 (en) 2005-01-27

Family

ID=32907683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/005244 Ceased WO2004074499A2 (en) 2003-02-20 2004-02-20 Combinatorial dna library for producing modified n-glycans in lower eukaryotes

Country Status (10)

Country Link
US (6) US7449308B2 (en)
EP (3) EP2316963B1 (en)
JP (2) JP4875486B2 (en)
AT (1) ATE469236T1 (en)
AU (2) AU2004213869B2 (en)
CA (2) CA2731504A1 (en)
DE (1) DE602004027351D1 (en)
ES (2) ES2394017T3 (en)
IL (2) IL170347A (en)
WO (1) WO2004074499A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647625B2 (en) 2004-07-26 2014-02-11 Biogen Idec Ma Inc. Anti-CD154 antibodies
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US8999671B2 (en) 2003-02-20 2015-04-07 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US9598682B2 (en) 2009-09-29 2017-03-21 Vib Vzw Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
CN107810271A (en) * 2014-11-20 2018-03-16 耶路撒冷希伯来大学伊萨姆研发公司 Composition and method for polypeptide of the production with the glycosylation pattern changed in plant cell

Families Citing this family (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024304A1 (en) * 2000-06-28 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US20060034828A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US8697394B2 (en) * 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US20060029604A1 (en) * 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7029872B2 (en) * 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US20060024292A1 (en) * 2001-12-27 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
US20060034829A1 (en) * 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
CA2471551C (en) * 2001-12-27 2014-09-30 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures
US6964784B2 (en) * 2002-03-07 2005-11-15 Optigenex, Inc. Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
KR101498588B1 (en) 2003-01-22 2015-03-05 로슈 글리카트 아게 FUSION CONSTRUCTS AND USE OF SAME TO PRODUCE ANTIBODIES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7507573B2 (en) * 2003-11-14 2009-03-24 Vib, Vzw Modification of protein glycosylation in methylotrophic yeast
CA2558635A1 (en) * 2004-03-17 2005-09-29 Glycofi, Inc. Method of engineering a cytidine monophosphate-sialic acid synthetic pathway in fungi and yeast
WO2005089047A2 (en) * 2004-03-18 2005-09-29 Glycofi, Inc. Glycosylated glucocerebrosidase expression in fungal hosts
JP2007535317A (en) 2004-04-15 2007-12-06 グライコフィ， インコーポレイテッド Production of galactosylated glycoproteins in lower eukaryotes
JP4954866B2 (en) 2004-04-29 2012-06-20 グライコフィ， インコーポレイテッド Methods for reducing or eliminating alpha-mannosidase resistant glycans in the production of glycoproteins
CA2573554A1 (en) * 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
EP1771479A1 (en) * 2004-07-21 2007-04-11 Glycofi, Inc. IMMUNOGLOBULINS COMPRISING PREDOMINANTLY A GlCNACMAN5GLCNAC2 GLYCOFORM
AU2005269759A1 (en) * 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
CN103145837A (en) * 2005-06-30 2013-06-12 Abbvie公司 IL-12/P40 binding proteins
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20140053410A (en) 2005-08-19 2014-05-07 아보트 러보러터리즈 Dual variable domain immunoglobulin and uses thereof
EP1942935A4 (en) * 2005-09-02 2009-12-23 Glycofi Inc IMMUNOGLOBULINS COMPRISING MAINLY A GLYCOFORM GLCNACMAN3GLCNAC2
AU2005336263A1 (en) * 2005-09-09 2007-03-15 Glycofi, Inc. Immunoglobulin comprising predominantly a man7GlcNAc2, Man8GlcNAc2 glycoform
CN101277974A (en) * 2005-09-30 2008-10-01 阿伯特有限及两合公司 Binding domains of proteins of the Repulsive Guide Molecule (RGM) protein family, functional fragments thereof and their uses
EP1954815B1 (en) * 2005-11-15 2015-02-25 GlycoFi, Inc. Production of glycoproteins with reduced o-glycosylation
RU2442793C2 (en) 2005-11-30 2012-02-20 Эбботт Лэборетриз ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES
PL1976877T5 (en) 2005-11-30 2017-09-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
MX2008009220A (en) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Compositions and methods for humanization and optimization of n-glycans in plants.
CN103255162A (en) * 2006-05-19 2013-08-21 格利科菲公司 Erythropoietin compositions
CA2651456A1 (en) * 2006-05-19 2007-11-29 Glycofi, Inc. Recombinant vectors
HUE052220T2 (en) 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 binding proteins
NZ576032A (en) 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
US8895004B2 (en) * 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
KR20090130029A (en) * 2007-03-07 2009-12-17 글리코파이, 인크. Preparation of Glycoprotein Modified with Fucosylation
BRPI0809042B1 (en) 2007-03-22 2021-08-31 Biogen Ma Inc. ISOLATED CD154-BINDING PROTEIN, ITS USE, AND COMPOSITION
JP5967861B2 (en) 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド Glycosylation of molecules
PE20090329A1 (en) * 2007-05-30 2009-03-27 Abbott Lab HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
EP2033971A1 (en) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP) binding domains of proteins of the Repulsive Guidance Molecule (RGM) protein family and functional fragments thereof and their application
US8637435B2 (en) * 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
EP2235198B1 (en) 2007-12-19 2018-08-29 GlycoFi, Inc. Yeast strains for protein production
JP2011514157A (en) * 2008-02-20 2011-05-06 グライコフィ， インコーポレイテッド Protein production vectors and yeast strains
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CA2715212A1 (en) 2008-03-03 2009-09-11 Glycofi, Inc. Surface display of recombinant proteins in lower eukaryotes
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102089430B (en) 2008-05-09 2015-02-04 Abbvie公司 Antibodies against receptor for progressive glycation end products (RAGE) and uses thereof
MX2010013059A (en) * 2008-05-30 2010-12-20 Glycofi Inc Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose.
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR20110016959A (en) 2008-06-03 2011-02-18 아보트 러보러터리즈 Dual Variable Domain Immunoglobulins and Uses thereof
KR20110040886A (en) 2008-07-08 2011-04-20 아보트 러보러터리즈 Prostaglandin E2 binding protein and uses thereof
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US8067339B2 (en) * 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
WO2010019487A1 (en) 2008-08-12 2010-02-18 Glycofi, Inc. Improved vectors and yeast strains for protein production: ca2+ atpase overexpression
EP2168987A1 (en) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
US20140205619A1 (en) * 2008-11-28 2014-07-24 Biolex Therapeutics, Inc. Recombinant avian influenza vaccine and uses thereof
SG171812A1 (en) * 2008-12-04 2011-07-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
NZ593905A (en) * 2009-01-29 2013-03-28 Abbott Lab Il-1 binding proteins
US8030026B2 (en) * 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
EP2401378B1 (en) 2009-02-25 2013-08-14 Merck Sharp & Dohme Corp. Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
US8815242B2 (en) * 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
MX2012002651A (en) 2009-09-01 2012-05-22 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
AR078651A1 (en) 2009-10-15 2011-11-23 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
JP2013507921A (en) 2009-10-16 2013-03-07 メルク・シャープ・エンド・ドーム・コーポレイション Process for the production in Pichia pastoris of proteins lacking detectable cross-linking activity against antibodies against host cell antigens
UY32979A (en) * 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
JP2013509180A (en) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Method for producing a recombinant protein having improved secretion efficiency
EP2494050A4 (en) * 2009-10-30 2013-10-30 Merck Sharp & Dohme FACTOR FOR STIMULATING GRANULOCYTES AND MONOCYTES PRODUCED IN GLYCOMODIFIED PICHIA PASTORIS
CN102725396A (en) 2009-10-30 2012-10-10 默沙东公司 Method for producing therapeutic proteins in pichia pastoris lacking dipeptidyl aminopeptidase activity
US8420083B2 (en) * 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
US20130053550A1 (en) 2009-11-19 2013-02-28 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
PH12012501070A1 (en) * 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
BR112012020882A2 (en) 2010-02-24 2015-11-03 Merck Sharp & Dohme methods for producing a heterologous glycoprotein and for producing a glycoprotein composition, host cell, glycoprotein composition, and use of recombinant pichia pastoris.
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
TWI500427B (en) 2010-05-14 2015-09-21 Abbvie Inc Il-1 binding proteins
AU2011258425B2 (en) 2010-05-27 2015-12-10 Merck Sharp & Dohme Llc Method for preparing antibodies having improved properties
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
CA2806148A1 (en) * 2010-07-30 2012-02-02 Glycode A yeast artificial chromosome carrying the mammalian glycosylation pathway
US20120135461A1 (en) * 2010-07-30 2012-05-31 William James Cook Production of glycoproteins with reduced o-glycosylation comprising the use of an alpha-1,2-mannosidase
KR20130100118A (en) 2010-08-03 2013-09-09 아비에 인코포레이티드 Dual variable domain immunoglobulins and uses therof
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
ES2665954T3 (en) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP6131190B2 (en) 2010-09-29 2017-05-17 オキシレイン ユーケー リミテッド Demannosylation of phosphorylated N-glycans
BR112013007616B1 (en) 2010-09-29 2023-01-24 Oxyrane Uk Limited METHODS FOR DECAPPING ("UNCAPPING") PORTIONS OF MANNOSE-1-PHOSPHO-6-MANNOSE AND DEMANNOSYLING PHOSPHORYLATED N-GLYCANS TO A GLYCOPROTEIN, FOR DIRECTING A GLYCOPROTEIN INTO A MAMMALIAN CELL, AND FOR CONVERTING A GLYCOPROTEIN IN A FIRST WAY THAT DOES NOT SUBSTANTIALLY BINDING TO A MANNOSE-6-PHOSPHATE RECEPTOR IN A SECOND WAY THAT SUBSTANTIALLY BINDS TO A MANNOSE-6-PHOSPHATE RECEPTOR ON A MAMMALIAN CELL
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
MX2013007332A (en) 2010-12-21 2014-01-23 Abbvie Inc Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use.
WO2012115903A2 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Yeast strain for the production of proteins with modified o-glycosylation
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
AU2012258907A1 (en) 2011-05-25 2013-11-07 Merck Sharp & Dohme Corp. Method for preparing Fc-containing polypeptides having improved properties
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
CN103827134A (en) 2011-07-20 2014-05-28 泽普泰恩股份有限公司 Polypeptide separation methods
AU2012328921B2 (en) 2011-10-24 2017-05-11 Abbvie Inc. Immunobinders directed against TNF
AR088513A1 (en) 2011-10-24 2014-06-18 Abbvie Inc IMMUNO LINKERS AGAINST SCLEROSTINE
CN104114183A (en) 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 CTP-based insulin analogs for treatment of diabetes
AR089529A1 (en) 2011-12-30 2014-08-27 Abbvie Inc UNION PROTEINS SPECIFIC DUALS DIRECTED AGAINST IL-13 AND / OR IL-17
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
CN104105789A (en) * 2012-02-16 2014-10-15 默沙东公司 Methods for reducing mannosyltransferase activity in yeast
CA2867237C (en) 2012-03-15 2024-01-02 Wouter Vervecken Methods and materials for treatment of pompe's disease
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
DK2852610T3 (en) 2012-05-23 2018-09-03 Glykos Finland Oy PRODUCTION OF FUCOSYLED GLYCOPROTEIN
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
AR091755A1 (en) 2012-07-12 2015-02-25 Abbvie Inc PROTEINS OF UNION TO IL-1
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9708387B2 (en) 2012-09-11 2017-07-18 Centre For Bioseparation Technology-Vit Methods for producing recombinant factor VIII chains from non-filamentous fungi, their functional reconstitution and applications thereof
US20150246118A1 (en) 2012-10-26 2015-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
PE20151179A1 (en) 2012-11-01 2015-09-12 Abbvie Inc DUAL ANTI-VEGF / DLL4 VARIABLE DOMAIN IMMUNOGLOBULINS AND USES OF THEM
WO2014093240A1 (en) 2012-12-10 2014-06-19 The General Hospital Corporation Bivalent il-2 fusion toxins
WO2014090948A1 (en) 2012-12-13 2014-06-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Serpin spn4a and biologically active derivatives thereof for use in the treatment of cancer
JP6408487B2 (en) 2012-12-18 2018-10-24 ザ ロックフェラー ユニバーシティ Glycan modified anti-CD4 antibodies for prevention and therapy of HIV
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
US9458244B2 (en) 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
EP2938637A2 (en) 2012-12-28 2015-11-04 AbbVie Inc. Multivalent binding protein compositions
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
EP2948177A1 (en) 2013-01-22 2015-12-02 AbbVie Inc. Methods for optimizing domain stability of binding proteins
EP2964668B1 (en) * 2013-03-06 2019-11-27 Protalix Ltd. Tnf alpha inhibitor polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
US9944689B2 (en) 2013-03-07 2018-04-17 The General Hospital Corporation Human CTLA4 mutants and use thereof
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
JP6538645B2 (en) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Insulin-incretin complex
MX362075B (en) 2013-03-14 2019-01-07 Abbott Lab Hcv antigen-antibody combination assay and methods and compositions for use therein.
KR20160021075A (en) * 2013-03-14 2016-02-24 글리코비아, 인크. Oligosaccharide compositions, glycoproteins and methods to produce the same in prokaryotes
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CN105378099B (en) 2013-03-14 2021-05-11 雅培制药有限公司 HCV core lipid binding domain monoclonal antibodies
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
JP2016515120A (en) 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Treatment and prevention of acute kidney injury using anti-alpha Vbeta5 antibody
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
WO2015044379A1 (en) 2013-09-27 2015-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A dyrk1a polypeptide for use in preventing or treating metabolic disorders
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
TWI731535B (en) 2014-03-21 2021-06-21 美商艾伯維有限公司 Anti-egfr antibodies and antibody drug conjugates
AU2015293949B2 (en) 2014-07-21 2019-07-25 Teknologian Tutkimuskeskus Vtt Oy Production of glycoproteins with mammalian-like N-glycans in filamentous fungi
AR104469A1 (en) * 2014-08-08 2017-07-26 Glycovaxyn Ag GUEST CELLS MODIFIED FOR USE IN PRODUCTION OF BIOCONJUGATES
CA2957722C (en) 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
CN108271356A (en) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 incretin-insulin conjugate
WO2016077457A1 (en) 2014-11-11 2016-05-19 Clara Foods Co. Methods and compositions for egg white protein production
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3265567B1 (en) 2015-03-02 2020-07-29 Conagen Inc. Regulatory elements from labyrinthulomycetes microorganisms
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
JP6518917B2 (en) 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド Anti-CD40 antibody and use thereof
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme An antibody that inactivates the human pneumonia virus
BR112018012352A2 (en) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anti-lag3 antibodies and antigen binding fragments
JP7014724B2 (en) 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド Tandem-type Fab immunoglobulin and its use
EP3445393B1 (en) 2016-04-20 2026-01-14 Merck Sharp & Dohme LLC Cmv neutralizing antigen binding proteins
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
CN109641962A (en) 2016-06-08 2019-04-16 艾伯维公司 Anti-B7-H3 Antibodies and Antibody Drug Conjugates
CN109562190A (en) 2016-06-08 2019-04-02 艾伯维公司 Anti-EGFR Antibody Drug Conjugates
RS61828B1 (en) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antibodies and antibody drug conjugates
MX2018015272A (en) 2016-06-08 2019-08-12 Abbvie Inc Anti-cd98 antibodies and antibody drug conjugates.
CN116059201A (en) 2016-06-08 2023-05-05 艾伯维公司 Anti-EGFR Antibody Drug Conjugate
MX2018015284A (en) 2016-06-08 2019-09-18 Abbvie Inc Anti-egfr antibody drug conjugates.
JP2019526529A (en) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド Anti-B7-H3 antibody and antibody drug conjugate
MX2018015268A (en) 2016-06-08 2019-08-12 Abbvie Inc Anti-cd98 antibodies and antibody drug conjugates.
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CA3032430A1 (en) 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
EP3535385A4 (en) * 2016-11-01 2020-06-17 Conagen Inc. EXPRESSION OF MODIFIED GLYCOPROTEINS AND GLYCOPEPTIDES
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
WO2018098370A1 (en) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-CUB-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY-ACTIVE SUBSTANCE CONJUGATES AND METHOD FOR USE THEREOF
TWI796329B (en) 2017-04-07 2023-03-21 美商默沙東有限責任公司 Anti-ilt4 antibodies and antigen-binding fragments
JP7160833B2 (en) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． anti-SIRP alpha antibody
WO2018195302A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
BR112020017701A2 (en) 2018-03-12 2020-12-29 Zoetis Services Llc ANTI-NGF ANTIBODIES AND METHODS OF THE SAME
CN112074541A (en) 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins prepared therefrom
AU2019339469A1 (en) 2018-09-13 2021-03-11 Immune-Onc Therapeutics, Inc. Novel LILRB4 antibodies and uses thereof
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
CN109439552B (en) * 2018-12-26 2020-01-21 山东百龙创园生物科技股份有限公司 Aspergillus oryzae BLCY-006 and application thereof in preparation of galactooligosaccharides
CN109932445A (en) * 2019-03-19 2019-06-25 北京泰德制药股份有限公司 A kind of evaluation method of a variety of charge isomer N sugar chain structures of glycoprotein
FI13395Y1 (en) 2019-07-11 2023-06-06 Clara Foods Co Compositions containing a recombinant ovomucoid protein
US12096784B2 (en) 2019-07-11 2024-09-24 Clara Foods Co. Protein compositions and consumable products thereof
US10927360B1 (en) 2019-08-07 2021-02-23 Clara Foods Co. Compositions comprising digestive enzymes
CN115943157A (en) 2020-01-21 2023-04-07 耶路撒冷希伯来大学伊森姆研究发展公司 Utilization of plant protein homologues in culture medium
KR20220137698A (en) 2020-02-05 2022-10-12 라리마 테라퓨틱스, 인코포레이티드 TAT peptide binding protein and uses thereof
CN115551894A (en) 2020-03-12 2022-12-30 以明生物免疫医疗公司 Novel Anti-LILRB4 Antibodies and Derivatives
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
JP2023524464A (en) 2020-04-30 2023-06-12 サイロパ ビー．ブイ． Anti-CD103 antibody
CN116723856A (en) 2020-06-25 2023-09-08 默沙东有限责任公司 High-affinity antibody targeting TAU phosphorylated at serine 413
EP4255451A4 (en) 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System METHODS FOR IDENTIFICATION OF LILRB BLOCKING ANTIBODIES
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
WO2023007468A1 (en) 2021-07-30 2023-02-02 Helaina, Inc. Methods and compositions for protein synthesis and secretion
DK4186529T3 (en) 2021-11-25 2025-08-25 Veraxa Biotech Gmbh IMPROVED ANTIBODY-PAYLOAD CONJUGATES (APC) MANUFACTURED BY SITE-SPECIFIC CONJUGATION USING GENETIC CODE EXPANSION
JP2024543916A (en) 2021-11-25 2024-11-26 ヴェラクサ バイオテック ゲーエムベーハー Improved antibody-payload complexes (APCs) prepared by site-specific conjugation using genetic code expansion
CN114231553A (en) * 2021-12-24 2022-03-25 浙江工业大学 High-throughput screening method of signal peptide library based on fluorescent probe Rho-IDA-CoII
EP4309666A1 (en) 2022-07-21 2024-01-24 Technische Universität Dresden M-csf for use in the prophylaxis and/or treatment of viral infections in states of immunosuppression
US20260041734A1 (en) 2022-07-21 2026-02-12 Technische Universität Dresden M-csf for use in the prophylaxis and/or treatment of viral infections in states of immunosuppression
WO2024147113A1 (en) 2023-01-05 2024-07-11 Glycoera Ag Glycoengineered polypeptides targeting anti-podocyte autoantibodies and uses thereof
JP2026501773A (en) 2023-01-05 2026-01-16 グリコエラ アーゲー Glyco-modified polypeptide targeting immunoglobulin A and complex containing the same
WO2024147111A1 (en) 2023-01-05 2024-07-11 Glycoera Ag Glycoengineered polypeptides targeting anti-neutrophil autoantibodies and uses thereof
WO2024218743A1 (en) 2023-04-21 2024-10-24 Glycoera Ag Multi-functional molecules comprising glycans and uses thereof
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
TW202530255A (en) 2023-12-15 2025-08-01 法商亞維西亞有限公司 Anti il-1rap binding domains and antibody-drug conjugates thereof
WO2025215516A1 (en) 2024-04-08 2025-10-16 Glycoera Ag Glycoengineered polypeptides targeting igg4 autoantibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000856A2 (en) * 2000-06-30 2002-01-03 Flanders Interuniversity Institute For Biotechnology (Vib) Protein glycosylation modification in pichia pastoris
WO2002000879A2 (en) * 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
EP1211310A1 (en) * 1999-08-19 2002-06-05 Kirin Beer Kabushiki Kaisha Novel yeast variants and process for producing glycoprotein containing mammalian type sugar chain

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414329A (en) 1980-01-15 1983-11-08 Phillips Petroleum Company Biochemical conversions by yeast fermentation at high cell densities
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4617274A (en) 1981-10-29 1986-10-14 Phillips Petroleum Company Biochemical conversions by yeast fermentation at high cell densities
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
KR850004274A (en) 1983-12-13 1985-07-11 원본미기재 Method for preparing erythropoietin
US4808537A (en) 1984-10-30 1989-02-28 Phillips Petroleum Company Methanol inducible genes obtained from pichia and methods of use
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4885242A (en) 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4855231A (en) 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US5032516A (en) 1985-10-25 1991-07-16 Phillips Petroleum Company Pichia pastoris alcohol oxidase II regulatory region
US5166329A (en) 1985-10-25 1992-11-24 Phillips Petroleum Company DNA encoding the alcohol oxidase 2 gene of yeast of the genus Pichia
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US4925796A (en) 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5272066A (en) * 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US4857467A (en) 1986-07-23 1989-08-15 Phillips Petroleum Company Carbon and energy source markers for transformation of strains of the genes Pichia
US5002876A (en) 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4683293A (en) 1986-10-20 1987-07-28 Phillips Petroleum Company Purification of pichia produced lipophilic proteins
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5135854A (en) 1987-10-29 1992-08-04 Zymogenetics, Inc. Methods of regulating protein glycosylation
US5004688A (en) 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5122465A (en) 1989-06-12 1992-06-16 Phillips Petroleum Company Strains of pichia pastoris created by interlocus recombination
US5032519A (en) 1989-10-24 1991-07-16 The Regents Of The Univ. Of California Method for producing secretable glycosyltransferases and other Golgi processing enzymes
US5595900A (en) 1990-02-14 1997-01-21 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5324663A (en) 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
US5962294A (en) 1992-03-09 1999-10-05 The Regents Of The University Of California Compositions and methods for the identification and synthesis of sialyltransferases
US5602003A (en) 1992-06-29 1997-02-11 University Of Georgia Research Foundation N-acetylglucosaminyltransferase V gene
AU6663294A (en) 1993-05-14 1994-12-12 Upjohn Company, The Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase
US5484590A (en) 1993-09-09 1996-01-16 La Jolla Cancer Research Foundation Expression of the developmental I antigen by a cloned human cDNA encoding a member of a β-1,6-N-acetylglucosaminyltransferase gene family
US6300113B1 (en) 1995-11-21 2001-10-09 New England Biolabs Inc. Isolation and composition of novel glycosidases
US5683899A (en) * 1994-02-03 1997-11-04 University Of Hawaii Methods and compositions for combinatorial-based discovery of new multimeric molecules
US6069235A (en) * 1994-02-23 2000-05-30 Monsanto Company Method for carbohydrate engineering of glycoproteins
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
HU221001B1 (en) * 1994-03-17 2002-07-29 Merck Patent Gmbh. Anti-egfr single-chain fvs, anti-egfr antibodies
WO1995034663A1 (en) 1994-06-13 1995-12-21 Banyu Pharmaceutical Co., Ltd. Gene coding for glycosyltransferase and use thereof
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5849904A (en) 1994-12-22 1998-12-15 Boehringer Mannheim Gmbh Isolated nucleic acid molecules which hybridize to polysialyl transferases
US5834251A (en) 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
JP2810635B2 (en) 1995-04-03 1998-10-15 理化学研究所 New sugar chain synthase
JPH08336387A (en) 1995-06-12 1996-12-24 Green Cross Corp:The Sugar chain elongation protein derived from yeast of the genus Pichia and its DNA
US5910570A (en) 1995-11-13 1999-06-08 Pharmacia & Upjohn Company Cloned DNA encoding a UDP-GalNAc: polypeptide N-acetylgalactosaminy-ltransferase
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US7001998B2 (en) 1996-08-02 2006-02-21 The Austin Research Institute Nucleic acids encoding a chimeric glycosyltransferase
JP4246264B2 (en) 1996-12-12 2009-04-02 協和発酵キリン株式会社 Novel β1 → 4N-acetylglucosaminyltransferase and gene encoding it
US5945314A (en) 1997-03-31 1999-08-31 Abbott Laboratories Process for synthesizing oligosaccharides
US20040191256A1 (en) * 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US7029870B1 (en) * 1997-07-03 2006-04-18 Human Genome Sciences, Inc. Gabaa receptor epsilon subunits
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JPH11103158A (en) 1997-09-26 1999-04-13 Olympus Optical Co Ltd Flip chip mounting method and mounting structure on printed wiring board
US7244601B2 (en) 1997-12-15 2007-07-17 National Research Council Of Canada Fusion proteins for use in enzymatic synthesis of oligosaccharides
JPH11221079A (en) 1998-02-04 1999-08-17 Kyowa Hakko Kogyo Co Ltd Glycosyltransferase and DNA encoding the enzyme
WO1999040208A1 (en) 1998-02-05 1999-08-12 The General Hospital Corporation In vivo construction of dna libraries
JP4334141B2 (en) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AU7849200A (en) 1999-10-01 2001-05-10 University Of Victoria Innovation And Development Corporation Mannosidases and methods for using same
JP2003514541A (en) 1999-11-19 2003-04-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 18 human secreted proteins
AU2001241541A1 (en) 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
US6410246B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Highly diverse library of yeast expression vectors
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US20060257399A1 (en) * 2000-06-28 2006-11-16 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US20060034830A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060034828A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060029604A1 (en) 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US8697394B2 (en) * 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US20060024304A1 (en) 2000-06-28 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JP4655388B2 (en) 2001-03-05 2011-03-23 富士レビオ株式会社 Protein production method
EP1383800A4 (en) 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
WO2002097060A2 (en) 2001-05-25 2002-12-05 Incyte Genomics Inc. Carbohydrate-associated proteins
JP4742191B2 (en) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 Glycoprotein and method for producing the same
EP1423510A4 (en) * 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
CA2460621A1 (en) 2001-09-19 2003-03-27 Nuvelo, Inc. Novel nucleic acids and polypeptides
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
PL213948B1 (en) * 2001-10-25 2013-05-31 Genentech Inc Glycoprotein compositions
US20060034829A1 (en) 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
US20060024292A1 (en) 2001-12-27 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
CA2471551C (en) 2001-12-27 2014-09-30 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures
US7252933B2 (en) 2002-06-26 2007-08-07 Flanders Interuniversity Institute For Biotechnology Protein glycosylation modification in methylotrophic yeast
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US7514253B2 (en) 2003-05-16 2009-04-07 Glycofi, Inc. URA5 gene and methods for stable genetic integration in yeast
EP1696864B1 (en) 2003-12-24 2014-11-12 GlycoFi, Inc. Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins
AU2003287935B2 (en) * 2003-12-30 2008-02-28 Gumlink A/S Chewing gum comprising biodegradable polymers and having accelerated degradability
CA2558635A1 (en) 2004-03-17 2005-09-29 Glycofi, Inc. Method of engineering a cytidine monophosphate-sialic acid synthetic pathway in fungi and yeast
WO2005089047A2 (en) 2004-03-18 2005-09-29 Glycofi, Inc. Glycosylated glucocerebrosidase expression in fungal hosts
JP2007535317A (en) 2004-04-15 2007-12-06 グライコフィ， インコーポレイテッド Production of galactosylated glycoproteins in lower eukaryotes
JP4954866B2 (en) * 2004-04-29 2012-06-20 グライコフィ， インコーポレイテッド Methods for reducing or eliminating alpha-mannosidase resistant glycans in the production of glycoproteins
JP2008515772A (en) 2004-07-21 2008-05-15 グライコフィ， インコーポレイテッド Immunoglobulin predominantly containing Gal2GlcNAc2Man3GlcNAc2 glycoform
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
CA2573541A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a man3glcnac2 glycoform
CA2573554A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
EP1771479A1 (en) 2004-07-21 2007-04-11 Glycofi, Inc. IMMUNOGLOBULINS COMPRISING PREDOMINANTLY A GlCNACMAN5GLCNAC2 GLYCOFORM
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
WO2006071280A1 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a ga1g1cnacman5glcnac2 glycoform
US7849651B2 (en) * 2005-05-31 2010-12-14 Kubota Matsushitadenko Exterior Works, Ltd. Wall materials bracket and insulating wall structure
EP1942935A4 (en) 2005-09-02 2009-12-23 Glycofi Inc IMMUNOGLOBULINS COMPRISING MAINLY A GLYCOFORM GLCNACMAN3GLCNAC2
AU2005336263A1 (en) 2005-09-09 2007-03-15 Glycofi, Inc. Immunoglobulin comprising predominantly a man7GlcNAc2, Man8GlcNAc2 glycoform
US20080274162A1 (en) * 2007-05-04 2008-11-06 Jeffrey Nessa Method, composition, and delivery mode for treatment of prostatitis and other urogenital infections using a probiotic rectal suppository

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1211310A1 (en) * 1999-08-19 2002-06-05 Kirin Beer Kabushiki Kaisha Novel yeast variants and process for producing glycoprotein containing mammalian type sugar chain
WO2002000879A2 (en) * 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
WO2002000856A2 (en) * 2000-06-30 2002-01-03 Flanders Interuniversity Institute For Biotechnology (Vib) Protein glycosylation modification in pichia pastoris

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHIBA YASUNORI ET AL: "Production of human compatible high mannose-type (Man5GlcNAc2) sugar chains in Saccharomyces cerevisiae.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 41, 9 October 1998 (1998-10-09), pages 26298 - 26304, XP002202331, ISSN: 0021-9258 *
KALSNER INGE ET AL: "Insertion into Aspergillus nidulans of functional UDP-GlcNAc: alpha-3-D-mannoside beta-1,2-N-acetylglucosaminyl-transferase I, the enzyme catalysing the first committed step from oligomannose to hybrid and complex N-glycans.", GLYCOCONJUGATE JOURNAL, vol. 12, no. 3, 1995, pages 360 - 370, XP001073956, ISSN: 0282-0080 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8883483B2 (en) 2000-06-28 2014-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US8999671B2 (en) 2003-02-20 2015-04-07 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US8647625B2 (en) 2004-07-26 2014-02-11 Biogen Idec Ma Inc. Anti-CD154 antibodies
US9598682B2 (en) 2009-09-29 2017-03-21 Vib Vzw Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
CN107810271A (en) * 2014-11-20 2018-03-16 耶路撒冷希伯来大学伊萨姆研发公司 Composition and method for polypeptide of the production with the glycosylation pattern changed in plant cell
CN107810271B (en) * 2014-11-20 2021-09-28 耶路撒冷希伯来大学伊萨姆研发公司 Compositions and methods for producing polypeptides with altered glycosylation patterns in plant cells

Also Published As

Publication number Publication date
CA2731504A1 (en) 2004-09-02
ATE469236T1 (en) 2010-06-15
US20130217067A1 (en) 2013-08-22
US7935513B2 (en) 2011-05-03
WO2004074499A2 (en) 2004-09-02
EP1599596A2 (en) 2005-11-30
JP4875486B2 (en) 2012-02-15
IL198906A0 (en) 2010-02-17
EP2196540A2 (en) 2010-06-16
US20040018590A1 (en) 2004-01-29
JP5255016B2 (en) 2013-08-07
EP2316963B1 (en) 2013-04-10
US20150051381A1 (en) 2015-02-19
AU2010200666A1 (en) 2010-03-18
US7449308B2 (en) 2008-11-11
AU2004213869B2 (en) 2010-03-04
US20090155847A1 (en) 2009-06-18
AU2004213869A1 (en) 2004-09-02
US20120052530A1 (en) 2012-03-01
ES2415955T3 (en) 2013-07-29
US20090209024A1 (en) 2009-08-20
EP1599596B1 (en) 2010-05-26
EP2316963A1 (en) 2011-05-04
JP2010207235A (en) 2010-09-24
AU2010200666B2 (en) 2012-08-16
EP2196540A3 (en) 2010-09-22
CA2516440A1 (en) 2004-09-02
EP2196540B1 (en) 2012-07-04
IL170347A (en) 2011-10-31
DE602004027351D1 (en) 2010-07-08
US8883483B2 (en) 2014-11-11
US8067551B2 (en) 2011-11-29
US8877462B2 (en) 2014-11-04
ES2394017T3 (en) 2013-01-15
JP2006518601A (en) 2006-08-17

Similar Documents

Publication Publication Date Title
EP2196540A3 (en) Combinatorial DNA library for producing modified N-Glycans in lower eukaryotes
WO2004074458A3 (en) N-acetylglucosaminyltransferase iii expression in lower eukaryotes
MXPA04006357A (en) Methods to engineer mammalian-type carbohydrate structures.
WO2007130638A3 (en) Production of sialylated n-glycans in lower eukaryotes
Bydlinski et al. The contributions of individual galactosyltransferases to protein specific N-glycan processing in Chinese Hamster Ovary cells
DeAngelis et al. Chemoenzymatic synthesis of glycosaminoglycans: re-creating, re-modeling and re-designing nature's longest or most complex carbohydrate chains
Oikawa et al. Golgi-localized enzyme complexes for plant cell wall biosynthesis
McArthur et al. Glycosyltransferase engineering for carbohydrate synthesis
Ross et al. Higher plant glycosyltransferases
Krainer et al. Knockout of an endogenous mannosyltransferase increases the homogeneity of glycoproteins produced in Pichia pastoris
Zervosen et al. A novel three-enzyme reaction cycle for the synthesis of N-acetyllactosamine with in situ regeneration of uridine 5 ‘-diphosphate glucose and uridine 5 ‘-diphosphate galactose
Lv et al. Advancing recombinant protein expression in Komagataella phaffii: opportunities and challenges
Bohlender et al. Stable protein sialylation in Physcomitrella
CN108026558B (en) Cells producing glycoproteins with altered N-and O-glycosylation patterns, and methods and uses thereof
Zhao et al. Engineering the thermostability of sucrose synthase by reshaping the subunit interaction contributes to efficient UDP-glucose production
Saqib et al. Molecular characteristics of plant UDP-arabinopyranose mutases
Mathieu-Rivet et al. Chlamydomonas reinhardtii: protein glycosylation and production of biopharmaceuticals
Durin et al. Metalloglycobiology: The power of metals in regulating glycosylation
Ebert et al. Nucleotide sugar transporters: orchestrating luminal glycosylation in plants
Ehrlich et al. Xyloglucan xylosyltransferase 1 displays promiscuity toward donor substrates during in vitro reactions
Auxillos et al. Multiplex genome engineering for optimizing bioproduction in Saccharomyces cerevisiae
WO2005056570A3 (en) Production of amino sugars
Khan et al. Strategies for humanizing glycosylation pathways and producing recombinant glycoproteins in microbial expression systems
Zhang et al. Multiprotein complexes of plant glycosyltransferases involved in their function and trafficking
Shimma et al. Expression of human glycosyltransferase genes in yeast as a tool for enzymatic synthesis of sugar chain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006503788

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2516440

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004213869

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1844/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004713437

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004213869

Country of ref document: AU

Date of ref document: 20040220

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004213869

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004713437

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 198906

Country of ref document: IL